利妥昔单抗联合ABVD方案治疗霍奇金淋巴瘤合并自身免疫性溶血性贫血一例并文献复习

Rituximab combined with ABVD regimen in treatment of Hodgkin lymphoma with autoimmune hemolytic anemia:report of one case and review of literature

目的探讨利妥昔单抗联合ABVD(表柔比星、博来霉素、长春地辛、达卡巴嗪)方案对霍奇金淋巴瘤(HL)合并自身免疫性溶血性贫血(AIHA)的疗效。方法回顾性分析2019年11月河南省肿瘤医院收治的1例HL合并AIHA患者的临床资料,并进行文献复习。结果患者行左颈部淋巴结活组织检查以及骨髓活组织检查,并完善淋巴瘤相关基因突变及全谱遗传病基因检测,诊断为HL(结节硬化型Ⅳ期)合并AIHA,给予6个周期利妥昔单抗联合ABVD方案治疗后评估疗效,贫血得到纠正,HL也获得完全缓解。结论利妥昔单抗联合ABVD方案治疗HL合并AIHA的患者具有较好的效果。

Objective To explore the efficacy of rituximab combined with ABVD(epirubicin+bleomycin+vindesine+dacarbazine)regimen in treatment of Hodgkin lymphoma(HL)complicated with autoimmune hemolytic anemia(AIHA).Methods The clinical data of 1 HL patient complicated with AIHA in November 2019 in Henan Cancer Hospital were retrospectively analyzed,and literatures were reviewed.Results The patient received left cervical lymph node biopsy and bone marrow biopsy,and then lymphoma-related gene mutations and whole genetic genome detection were performed.The patient was diagnosed as HL(tuberous sclerosis in stageⅣ)complicated with AIHA.After 6 cycles of rituximab combined with ABVD regimen,the efficacy was evaluated.This patient's anemia was recovered,and HL also achieved complete remission.Conclusions Rituximab combined with ABVD regimen is effective in treatment of HL patients complicated with AIHA.